2nd July 2015 -
Reference : Movement Disorders [2015] Jun 12 [Epub ahead of print] (M.Murata, K.
Hasegawa, I.Kanazawa, J.Fukasaka, K.Kochi, R.Shimazu)
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/26094993
http://www.viartis.net/parkinsons.disease/news.htm
Zonisamide, despite being an anti-epileptic, reduced "off" time in Parkinson's Disease during
clinical trials. Zonisamide is presently being assessed for use in the treatment of Parkinson's
Disease. Zonisamide activates dopamine biosynthesis by increasing the level of mRNA of
tyrosine hydroxylase, which is the enzyme responsible for dopamine formation. For more
information on zonisamide go to : http://www.rxlist.com/zonegran-drug.htm
To determine the efficacy of zonisamide for the treatment of
"off" time in Parkinson's Disease, people with Parkinson's
Disease who had wearing-off received a placebo for 4
weeks and were then treated for 12 weeks with either 25mg
per day zonisamide, 50 mg per day zonisamide, or placebo,
in addition to their previous therapy. The "off" time
significantly reduced by 45 minutes when taking 50mg
zonisamide per day.
Although the incidence of somnolence was just a bit higher for zonisamide, the incidences of
other adverse events, including dyskinesia or hallucinations, for zonisamide were comparable
to those of only a placebo.
The study provides evidence that confirms the efficacy of zonisamide 50 mg per day for
reduction in "off" time in people with Parkinson's Disease with wearing-off phenomena.
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/26094993
http://www.viartis.net/parkinsons.disease/news.htm
No comments:
Post a Comment